La cadena de opciones muestra datos clave de las opciones de acciones de FIGS a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para FIGS..

FIGS (NYSE:FIGS) Bolsa, Cadena de Opciones

FIGS INC-CLASS A

FIGS

FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.

Pinterest,Mobile,App,On,The,Screen,Smartphone,Iphone,Closeup.,Pinterest

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CETY

CRVS

GDOT

GMED

IOVA

JBIO

NCNA

PINS

PROF

SHPH

TMDX

VEEE

WOLF

WORX

ZKIN

Pinterest sube un 12,7 % tras superar ingresos del primer trimestre y aumentar usuarios mensuales. Otras acciones también reaccionan.

Acciones de Pinterest (PINS) se disparan un 13%; Aquí están 20 acciones que se mueven en el premercado

FIGS Inc

William Blair analyst Ryan Merkel initiates coverage on James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) with a Outperform rating.

Initiation

Analyst Ratings

William Blair Initiates Coverage On James Hardie Industries with Outperform Rating

Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Overweight and maintains $8 price target.

Price Target

Reiteration

PRQR

Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target

Major U.S. corporations are increasingly adding Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to their balance sheets, raising concerns about potential market risks as the trend accelerates under <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46131815/trumps-crypto-advisor-david-sacks-says-july-will-be-a-big-month-says-president-supports-legislation-on-market-structure-and-stablecoins">President Donald Trump's administration</a>.
Companies like Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are driving this surge, recently announcing plans to invest around $2.5 billion in Bitcoin through stock and debt sales.
Trump's pro-crypto stance has significantly reshaped the regulatory landscape, Politico <a href="https://www.politico.com/news/2025/06/27/trump-bitcoin-treasury-wall-street-warren-00423673">reported</a>.
His administration's rollback of enforcement actions and push for crypto-friendly legislation have emboldened corporate America to embrace digital assets more aggressively. 
According to Standard Chartered, more than 60 publicly traded companies globally now hold over 673,000 Bitcoin, valued at approximately $75 billion as of May's end. 
Trump Media, among the most notable participants, is allocating substantial capital to Bitcoin, with CEO Devin Nunes calling it "an apex instrument of financial freedom."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46121954/retail-investors-can-now-trade-spacex-shares-heres-how">Retail Investors Can Now Trade SpaceX Shares: Here&#8217;s How</a>
Trump family members, including Eric Trump, have publicly championed Bitcoin adoption at recent industry events, reflecting a broader shift in sentiment where companies view Bitcoin as a viable treasury asset alongside traditional holdings like U.S. Treasuries.
Despite the enthusiasm, several lawmakers and experts are voicing caution. 
Senator Elizabeth Warren (D-Mass.) has warned that widespread corporate exposure to Bitcoin could amplify the economic fallout in the event of a future crypto crash, potentially leading to business failures and job losses across sectors.
Nic Carter, a partner at Castle Island Ventures, likened the current buildup of corporate Bitcoin holdings to &#8220;kindling&#8221; that could fuel a market collapse. 
Columbia University's Omid Malekan echoed the sentiment, pointing out the crypto industry's repeated cycles of overconfidence followed by painful corrections.
The practice, popularized by Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), has since been adopted by other firms like Japan's Metaplanet (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>) and the Trump-backed American Bitcoin.
These companies raise capital at low cost through stock and debt markets and use the proceeds to buy Bitcoin, a strategy that has driven their stock prices higher.
However, critics like investor Jim Chanos argue that these gains are unsustainable. 
He believes the valuations of such firms could plummet if Bitcoin prices fall, warning that many of these companies are not adding meaningful value beyond buying Bitcoin itself.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46119440/why-did-this-uae-based-fund-just-purchase-100m-worth-of-trump-affiliated-wlfi-tokens">Why Did This UAE-Based Fund Just Purchase $100M Worth Of Trump-Affiliated WLFI Tokens?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Short Sellers

$BTC

MSTR

MTPLF

Corporate Bitcoin Buying Spree: Booming Strategy Or Ticking Financial Time Bomb?

WIIM

BURU

NUBURU shares are trading higher after the company said the regulatory approval process for its acquisition of Tekne SpA is progressing 'positively and in line with expectations.'

LAES

WKEY

WISeKey's Subsidiary WISeSat.Space Is On Target To Deploy 100-Satellite Constellation By 2027 In Cooperation With WISekey And SEALSQ

Government

Regulations

NUBURU Says Regulatory Approval Process For Acquisition Of Tekne SpA Is 'progressing positively and in line with expectations'

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and maintains $96 price target.

Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target

Stock Split

HSDT

Helius Medical Technologies Announces 1-For-50 Reverse Split Of Its Class A Common Stock

Offerings

OTRK

Ontrak Health Prices Public Offering Of 6,666,667 Shares And 26,666,668 Warrants At Combined Public Offering Price Of $0.60 Per Share And Accompanying Warrant; Gross Proceeds ~$4M

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program.
Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway.
The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026.
The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025.

OMER

Omeros Submits MAA To EMA For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

CISO

CISO Global Files Renewal Of S-3 Shelf Registration, Reducing Total Shelf From $300M To $100M

Macro Economic Events

Econ #s

Economics

US PCE Price index (YoY) (May) +2.3% vs +2.3% Est.

USA Core PCE Price Index (MoM) (May) +0.2% vs +0.1% Est.

PCE Price Index MoM For For May 0.1% Vs 0.1% Expected

Macro Notification

General

Core PCE Price Index (YoY) (May) +2.7% vs +2.6% Est.

JMP Securities analyst Patrick Walravens reiterates Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Market Outperform and maintains $17 price target.

JMP Securities Reiterates Market Outperform on Sprinklr, Maintains $17 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Market Outperform and maintains $86 price target.

CRSP

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Jefferies analyst Peter Abramowitz initiates coverage on Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) with a Buy rating and announces Price Target of $8.

Jefferies Initiates Coverage On Armada Hoffler Properties with Buy Rating, Announces Price Target of $8

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) showcased an <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence (AI) model</a> designed to identify gastric cancer, co-developed by Alibaba&#8217;s Damo Academy and the Zhejiang Cancer Hospital.
The model can detect gastric cancer, even in early stages, by scanning computed tomography (CT) images. The AI model known as Grape derived its name from the &#8220;gastric cancer risk assessment procedure.&#8221;
Grape can analyze three-dimensional CT scans to detect and segment gastric cancer, also known as stomach cancer, SCMP <a target="_blank" href="https://www.scmp.com/tech/article/3315931/alibaba-touts-worlds-first-ai-model-detect-stomach-cancer-even-early-stages" rel="noreferrer noopener">reported</a> on Thursday.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46069690/alibaba-accelerates-global-ai-push-targets-overseas-data-centers" rel="noreferrer noopener">Alibaba Accelerates Global AI Push, Targets Overseas Data Centers</a>
Diagnosis of gastric cancer currently requires an endoscopy, prompting the insertion of a camera and tiny biopsy instruments through the throat.
Citing a paper published in Nature Medicine on Tuesday, SCMP reported that the Grape model significantly outperformed radiologists.
This initiative underscores Alibaba&#8217;s strategic move to unlock value by integrating AI technology into its various operations, including healthcare.
Following a similar approach, Alibaba had already made a breakthrough in detecting pancreatic cancer in 2023, showcasing a growing focus on applying its AI expertise to critical medical challenges.
Beyond healthcare, Alibaba is also making waves in the general AI landscape. Last week, Alibaba revealed new Qwen3 AI models, <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45975004/alibaba-updates-llms-to-power-ai-on-apple-devices-in-china" rel="noreferrer noopener">signaling a possible</a> collaboration or rollout with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in China amid rising local AI demand.
Alibaba co-founder and Chair&nbsp;Joe Tsai opted to <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45925331/alibaba-co-founder-sees-open-source-qwen-driving-cloud-demand" rel="noreferrer noopener">open-source its</a> Qwen models, citing their potential to drive demand for&nbsp;AI&nbsp;applications and cloud computing.
Open source gives the public access to a software program&#8217;s source code, allowing third-party developers to modify or scale up its capabilities.
IMARC Group&nbsp;expects&nbsp;the global <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45816525/alibaba-releases-new-open-source-ai-models-with-multilingual-and-code-support" rel="noreferrer noopener">open-source intelligence</a> market to reach&nbsp;$58.0 billion&nbsp;by 2033, at a&nbsp;CAGR of 15.93%&nbsp;from 2025 to 2033.
Price Action:&nbsp;BABA stock traded higher by 0.11% to $114.06 premarket at&nbsp;the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Asia

Health Care

Tech

Media

AAPL

BABA

Alibaba's AI Model Outperforms Radiologists In Early Gastric Cancer Detection

Press Releases

Applied Fundamental Research Issues Open Letter to FIGS Management and its Board of Directors

FIGS Announces Date of Fourth Quarter and Full Year 2024 Earnings Release, Conference Call and Webcast

FIGS Announces Participation in the Raymond James 46th Annual Institutional Investors Conference

Legal

Inari Medical, Figs Inc, Fastly, and Ryvyl Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

FIGS Releases Fourth Quarter and Full Year 2024 Financial Results

FIGS Adds Digital Marketing Executive Jerry Jao as New Independent Director to Its Board of Directors

FIGS Announces Date of First Quarter 2025 Earnings Release, Conference Call and Webcast

Jeffrey Lawrence Appointed Chairman of Joe & the Juice

FIGS Releases First Quarter 2025 Financial Results

FIGS Announces Participation in the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference

Comments

FIGS

FIGS (FIGS) Opciones

FIGS (NYSE:FIGS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL